Skip to content

NASDAQ · micro · thesis board

SGMO Sangamo Therapeutics

ZFN gene therapy / genome regulation

View race

Thesis

Editorial summary — not a primary filing

Zinc finger gene therapy collaborations; runway is the binding constraint.

Next gate

2026-12-18EstimatedPh3 readout

Partnered Ph3 update

127 days · Estimated: Estimated window

Survive-to-Event

tight

Cash roughly covers the next gate — financing risk is elevated.

Unverified estimate — not from a live SEC parse

Cash runway (~139d)100%
Days to gate (127d)91%
Show math

$55M cash ÷ $12M/mo burn ≈ 139 days. Source: curated SEC quarter figures.

Cash $55M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
PFEApprovedokBMRNApprovedokNVOFiledok

Risks

  • Severe runway pressure
  • Partner dependence
  • Clinical lag
  • Dilution

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT04370054as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01